• Panel Explores the Rapidly Evolving Field of Genetic Medicines

    Bio-IT World | In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases. In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases.

    Aug 27, 2024
  • The Art of Building Techbio Teams

    Bio-IT World | The biotech industry is experiencing a significant shift as technology and biology converge. This intersection, often called Techbio, is opening up new possibilities for addressing health and environmental challenges.

    Aug 23, 2024
  • First Clinical Trial of ‘Paradoxical Intervention’ for Cancer to Begin Soon

    Bio-IT World | Cancer cells are “not like superheroes that have no vulnerabilities." Most current therapies try to block the signaling to prevent cancer’s uncontrolled division, but inevitably tumor cells resist the blockage and become far less responsive to subsequent therapy.

    Aug 21, 2024
  • Mice Cleared of Senescent Cells Shown to Die Healthier—Not Just Live Longer

    Bio-IT World | By treating a particular brand of senescent cells, it is now possible to live healthier for longer—at least in mice. If the findings can be translated to humans, that could mean an extra decade of healthiness. Plenty of medicines are already available to help people live longer, but not necessarily with vitality.

    Aug 20, 2024
  • Standardized R&D Data Exchange is Here. Let’s Embrace It.

    Bio-IT World | Life sciences companies have spent much time and treasure working to streamline and improve product development. The drivers have been many, but two have stood out. The first is a desire to improve efficiency and optimize cost, because it’s good for business and the pocketbooks of patients we ultimately serve. The second is to boost material traceability, because product quality depends on it—and regulators demand it.

    Aug 16, 2024
  • A Skeptic Converts: Tom Plasterer’s move from Big Pharma to AI Startup

    Bio-IT World | For more than a dozen years, Tom Plasterer has held roles at AstraZeneca both in research IT and in more science-facing positions including translational medicine. Along the way, he was beating the drum for FAIR data—data that are Findable, Accessible, Interoperable and Reusable— and knowledge graphs, playing an active role in both the FAIR community and the Pistoia Alliance.

    Aug 14, 2024
  • Safe and Intriguing ‘Nature’s Drugs’ Taking on Complex Diseases

    Bio-IT World | The cost of bringing a drug to market has, by some estimates, ballooned to $3 billion and the central problem could be the “misapplication of technology.” Since completion of the Human Genome Project, the focus had shifted heavily toward orphan drugs with a single genetic target, suitable only to highly targeted genetic technology platforms.

    Aug 13, 2024